Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Trial Profile

Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs TRXE 002 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Kazia Therapeutics
  • Most Recent Events

    • 28 Mar 2018 According to a Kazia Therapeutics media release, initial data anticipated in 2Q 2018.
    • 11 Dec 2017 Novogen company name has changed to Kazia Therapeutics Limited.
    • 07 Aug 2017 According to a Novogen media release, the company anticipates MTD results in the first quarter of 2018 and the exploratory efficacy data from the additional patients will be available later in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top